These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34405005)

  • 1. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
    Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
    J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.
    Colton M; Purev E; Haverkos B; Bair S; Jasem J; Jacob A; Kamdar M
    Clin Lymphoma Myeloma Leuk; 2024 Nov; 24(11):778-782. PubMed ID: 39034202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
    Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
    Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
    Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.
    Tu S; Zhou X; Guo Z; Huang R; Yue C; He Y; Li M; Chen Y; Liu Y; Chang LJ; Li Y
    Front Oncol; 2019; 9():1350. PubMed ID: 31867275
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 8. Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma.
    Maluquer C; Bellosillo B; Mussetti A; Domingo-Domènech E; Parody R; Fernández-Ibarrondo L; Velasco R; Moreno-González G; Sanz G; Cortés M; Sureda A
    EJHaem; 2021 Feb; 2(1):109-111. PubMed ID: 35846093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.
    Ping N; Qu C; Li M; Kang L; Kong D; Chen X; Wu Q; Xia F; Yu L; Yao H; Yan L; Wu D; Jin Z
    Ann Transl Med; 2022 Mar; 10(6):298. PubMed ID: 35433994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL.
    Liu H; Yang C; Zhao X; Le J; Wu G; Wei J; Liang Y; Qian W
    Onco Targets Ther; 2020; 13():10797-10806. PubMed ID: 33122918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
    Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
    Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.
    Al-Mansour M; Al-Foheidi M; Ibrahim E
    Mol Clin Oncol; 2020 Oct; 13(4):33. PubMed ID: 32789017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of CT-Textural Features and Volume-Based PET Parameters in Comparison to Serologic Markers for Response Prediction in Patients with Diffuse Large B-Cell Lymphoma Undergoing CD19-CAR-T Cell Therapy.
    Reinert CP; Perl RM; Faul C; Lengerke C; Nikolaou K; Dittmann H; Bethge WA; Horger M
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
    Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
    Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Li C; Sun Y; Wang J; Tang L; Jiang H; Guo T; Liu L; Wu Y; Ai L; Xia L; Wu J; Lin Z; Qian Q; Hu Y; Mei H
    Front Immunol; 2021; 12():599493. PubMed ID: 34113336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy.
    Yan Z; Li L; Fu D; Wu W; Qiao N; Huang Y; Jiang L; Wu D; Hu Y; Zhang H; Xu P; Cheng S; Wang L; Lacin S; Muftuoglu M; Zhao W
    Front Med; 2023 Aug; 17(4):699-713. PubMed ID: 37060525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.
    Qu C; Ping N; Kang L; Liu H; Qin S; Wu Q; Chen X; Zhou M; Xia F; Ye A; Kong D; Li C; Yu L; Wu D; Jin Z
    J Immunother; 2020 Jan; 43(1):32-37. PubMed ID: 31219975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma.
    Zhou W; Chen W; Wan X; Luo C; Du X; Li X; Chen Q; Gao R; Zhang X; Xie M; Wang M
    Front Genet; 2021; 12():815679. PubMed ID: 35126471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.